Open AccessIntrathecal baclofen therapy in the management of drug-resistant muscle spasticity in patients with traumatic spinal cord injury
Author(s) -
И. Н. Морозов,
E D Isagulyan
Publication year - 2022
Publication title -
nejrohirurgiâ
Language(s) - English
Resource type - Journals
eISSN - 2587-7569
pISSN - 1683-3295
DOI - 10.17650/1683-3295-2021-23-4-44-49
Subject(s) - spasticity , baclofen , medicine , neurorehabilitation , spinal cord injury , spinal cord , anesthesia , pharmacotherapy , physical medicine and rehabilitation , rehabilitation , physical therapy , psychiatry , receptor , agonist
Neurorehabilitation of patients with spinal cord injury and severe muscle spasticity have always been one of the most challenging tasks for neurologists. Muscle spasticity significantly impairs patients’ quality of life and is often resistant to pharmacotherapy. Over the last 10 years, intrathecal baclofen therapy has become the most effective treatment for spasticity in Russia. In this study, we tried to systematize the data on intrathecal baclofen therapy in patients with spinal cord injury complicated by spasticity and to evaluate their treatment outcomes, as well as the incidence of adverse events. Our findings will ultimately help to clarify the need for intrathecal baclofen therapy in routine clinical practice.